MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism

B. Heim, S. Mangesius, F. Krismer, A. Hussl, G.K Wenning, E.R Gizewski, M. Schocke, W. Poewe, K. Seppi (Innsbruck, Austria)

Meeting: MDS Virtual Congress 2020

Abstract Number: 278

Keywords: Magnetic resonance imaging(MRI), Parkinsonism, Progressive supranuclear palsy(PSP)

Category: Neuroimaging (Non-PD)

Objective: To determine diagnostic accuracy of P/M, MRPI, and new indices termed P/M2.0 and MRPI2.0 (multiplying P/M and MRPI by third ventricle width/frontal horns width ratio [3rdV/FH]) in clinically unclassifiable parkinsonism (CUP).

Background: Differential diagnosis of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) from Parkinson’s disease (PD) can be difficult especially in the early disease stages. Based on their different pattern of infratentorial atrophy, the quantitative MR planimetric measurementsMR-Parkinsonism-Index (MRPI) and pons-to-midbrain area ratio (P/M) have been reported to be abnormal in PSP, differentiating PSP from PD or MSA with high diagnostic accuracy. However, yet, few data exist on the usefulness of these MR markers for the differentiation of early stage neurodegenerative parkinsonism.

Method: MR planimetric measurements were assessed in a cohort of 84 patients with CUP. For qualification as CUP, patients had to meet at least one of the following criteria: presence of two cardinal signs of parkinsonism if the patient presented without bradykinesia; parkinsonism of mild intensity; newly diagnosed untreated parkinsonism, or disease duration of less than 18 months. Moreover, they had to fulfill step two of the UK PD Society Brain Bank Diagnostic Criteria. All patients were regularly followed-up for at least 24 months and the clinical diagnosis at last visit was considered as final diagnosis. A final diagnosis of PD required confirmation after at least 4 years. Receiver Operating Characteristic (ROC) curves statistics with their area under the curve (AUCs) were calculated for the discrimination of PSP from non-PSP.

Results: Final diagnosis in the CUP cohort after clinical follow-up was: 55 PD, 12 MSA, and 17 PSP patients. PSP patients had significant higher MRPI and MRPI2.0 as well as P/M and P/M2.0 values compared with the other groups with overlapping individual values. AUCs in discriminating PSP from non-PSP were 0.91 for both the P/M and the MRPI and 0.98 for the P/M2.0 and the MRPI2.0.

Conclusion: Brainstem-derived MR planimetric measures yield high diagnostic accuracy for the discrimination of PSP from non-PSP parkinsonism in early disease stages. Because 3rdV enlargement is specifically involved in PSP, it seems that the inclusion of 3rdV width makes the P/M2.0 and the MRPI2.0 more powerful in differentiating early stage PSP patients than the P/M and MRPI.

To cite this abstract in AMA style:

B. Heim, S. Mangesius, F. Krismer, A. Hussl, G.K Wenning, E.R Gizewski, M. Schocke, W. Poewe, K. Seppi. Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/diagnostic-accuracy-of-mr-planimetry-in-clinically-unclassifiable-parkinsonism/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/diagnostic-accuracy-of-mr-planimetry-in-clinically-unclassifiable-parkinsonism/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley